on ONWARD MEDICAL NV (isin : NL0015000HT4)
ONWARD Medical's 2025 Performance and Pipeline Developments
ONWARD Medical reported its 2025 financial and operational outcomes, showcasing a solid US commercial presence and notable pipeline progress. The company sold 117 ARC-EX® Systems to over 80 US rehabilitation clinics, establishing significant market momentum. Regulatory highlights include receiving CE Mark for the ARC-EX System for clinic and home use, and FDA clearance for its home use in the US. Additionally, the FDA approved an investigational device exemption for ARC-IM®, advancing the Empower BP global pivotal study.
The company also made strides in science and technology, publishing in prominent journals and performing four ARC-BCI® Therapy trials. Financially, ONWARD Medical reported EUR 5.4 million in revenue, with equity capital increased by EUR 50.8 million. It closed the year with EUR 68.1 million in net cash.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ONWARD MEDICAL NV news